Cargando…

WXJ-202, a novel Ribociclib derivative, exerts antitumor effects against breast cancer through CDK4/6

Cyclin-dependent kinases 4 and 6 (CDK4/6) are key regulatory proteins in the cell division and proliferative cycle in humans. They are overactive in many malignant tumors, particularly in triple-negative breast cancer (TNBC). Inhibition of CDK4/6 targets can have anti-tumor effects. Here, we designe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ji, Jing, Liu, Wenwen, Xu, Yuxin, Xu, Zhou, Lv, Mingxiao, Feng, Jing, Lv, Jinyu, He, Xingbei, Zhang, Zhen, Xie, Mengru, Jing, Aixin, Wang, Xiujun, Ma, Jinming, Liu, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9894725/ https://www.ncbi.nlm.nih.gov/pubmed/36744210 http://dx.doi.org/10.3389/fphar.2022.1072194

Ejemplares similares

A novel ribociclib derivative WXJ-103 exerts anti-breast cancer effect through CDK4/6
por: Ji, Jing, et al.
Publicado: (2023)

VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression
por: Ji, Jing, et al.
Publicado: (2023)

Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
por: Braal, C. Louwrens, et al.
Publicado: (2020)

Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
por: Jin, Dan, et al.
Publicado: (2019)

Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
por: Jin, Xi-Feng, et al.
Publicado: (2021)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
por: Pribnow, Allison, et al.
Publicado: (2022)

Ribociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
por: Yap, Yoon‐Sim, et al.
Publicado: (2020)

Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma
por: Chen, Dehong, et al.
Publicado: (2020)

Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells
por: Choupani, Edris, et al.
Publicado: (2022)

New Adducts of Iriflophene and Flavonoids Isolated from Sedum aizoon L. with Potential Antitumor Activity
por: Li, Mingxiao, et al.
Publicado: (2017)

An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data
por: James, Alexander D., et al.
Publicado: (2020)

Ribociclib Induced Photosensitive Skin Lesions
por: Verma, Vaishnavi, et al.
Publicado: (2022)

Pathogenic bacteria characteristics and drug resistance in acute, delayed, and chronic periprosthetic joint infection: A retrospective analysis of 202 patients
por: Chang, Yu, et al.
Publicado: (2023)

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest
por: Wang, Jiayuan, et al.
Publicado: (2017)

The Peptide-Directed Lysosomal Degradation of CDK5 Exerts Therapeutic Effects against Stroke
por: Zhou, Ya-Fan, et al.
Publicado: (2019)

Ribociclib-induced Vitiligo: a Case Report
por: Silvestre Torner, Nicolás, et al.
Publicado: (2022)

Famitinib exerted powerful antitumor activity in human gastric cancer cells and xenografts
por: Ge, Sai, et al.
Publicado: (2016)

Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways
por: Chen, Zuhua, et al.
Publicado: (2017)

Ribociclib Inhibits P-gp-Mediated Multidrug Resistance in Human Epidermoid Carcinoma Cells
por: Zhang, Lei, et al.
Publicado: (2022)

Acacetin exerts antitumor effects on gastric cancer by targeting EGFR
por: Zhang, Guangtao, et al.
Publicado: (2023)

FBXO2 targets glycosylated SUN2 for ubiquitination and degradation to promote ovarian cancer development
por: Ji, Jing, et al.
Publicado: (2022)

Case Report of Probable DRESS Syndrome Associated with Ribociclib
por: Carneiro, Florian, et al.
Publicado: (2023)

Phase I trial of ribociclib with platinum chemotherapy in ovarian cancer
por: Coffman, Lan G., et al.
Publicado: (2022)

LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
por: Qiu, Jiahao, et al.
Publicado: (2022)

Evaluation of the antitumor activity of NOV202, a novel microtubule targeting and vascular disrupting agent
por: Rickardson, Linda, et al.
Publicado: (2017)

Arsenic Trioxide Cooperate Cryptotanshinone Exerts Antitumor Effect by Medicating Macrophage Polarization through Glycolysis
por: Jiang, Tao, et al.
Publicado: (2022)

Targeting PIN1 exerts potent antitumor activity in pancreatic ductal carcinoma via inhibiting tumor metastasis
por: Chen, Linying, et al.
Publicado: (2019)

Aloperine Exerts Antitumor Effects on Bladder Cancer in vitro
por: Zhang, Lijun, et al.
Publicado: (2020)

Antibody‐drug conjugate MORAb‐202 exhibits long‐lasting antitumor efficacy in TNBC PDx models
por: Furuuchi, Keiji, et al.
Publicado: (2021)

Ribociclib: a valuable addition to treatment options in breast cancer?
por: Bartsch, Rupert
Publicado: (2017)

Ribociclib and palbociclib-induced erythema multiforme: a case report
por: Vrana, Eleni, et al.
Publicado: (2022)

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib
por: Zhu, Zhimin, et al.
Publicado: (2023)

Diosgenin Exerts Antitumor Activity via Downregulation of Skp2 in Breast Cancer Cells
por: Liu, Yanling, et al.
Publicado: (2020)

MicroRNA-125b exerts antitumor functions in cutaneous squamous cell carcinoma by targeting the STAT3 pathway
por: Tian, Ke, et al.
Publicado: (2020)

Divaricoside Exerts Antitumor Effects, in Part, by Modulating Mcl-1 in Human Oral Squamous Cell Carcinoma Cells
por: Weng, Jing-Ru, et al.
Publicado: (2019)

An engineered PD-1-based and MMP-2/9-oriented fusion protein exerts potent antitumor effects against melanoma
por: Wei, Mulan, et al.
Publicado: (2018)

Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry
por: Martínez-Chávez, Alejandra, et al.
Publicado: (2019)

The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature
por: Botticelli, Andrea, et al.
Publicado: (2022)

PCC0208018 exerts antitumor effects by activating effector T cells
por: Ge, Minmin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_van9plnm23t48ntggfg5skq0rh